Lisata Therapeutics, Inc. (LSTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 7, 2025, relates to Lisata Therapeutics, Inc., a Delaware corporation trading on the Nasdaq Capital Market. The filing serves to disclose the Company's financial results for the second quarter ended June 30, 2025, pursuant to Regulation FD.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1 and the corporate presentation as Exhibit 99.2, which are incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The Company issued a press release and a slide presentation for investor conferences on August 7, 2025. The filing explicitly states that the information in Item 7.01, including the exhibits, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement under the Securities Act of 1933, except as expressly stated.
Key Facts for Investor Verification
- Verify the specific Q2 2025 financial results (revenue, net loss, cash position) in the press release attached as Exhibit 99.1.
- Review the corporate presentation (Exhibit 99.2) for updated clinical pipeline status and strategic outlook.
- Note that the financial data in this 8-K is not "filed" for liability purposes under Section 18 of the Exchange Act.
- Confirm the Company's status as a non-emerging growth company based on the unchecked box in the filing.